Mitchell E. Gross, MD, PhD

TitleAssociate Professor of Clinical Medicine
InstitutionUniversity of Southern California
AddressCSC 240
Health Sciences Campus
Los Angeles CA 90089-9075
Phone+1 310 272 7640
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    1989Phi Beta Kappa
    UCSD/Revelle College Academic1990Leadership Award
    1994Alpha Omega Alpha
    1994Hewlett Packard Award for Excellence in Internal Medicine
    1997  - 2002Specialty Training Advanced Research Fellowship
    1999Amgen Fellowship Research Award
    1999Rhone Phoulenc Rorer Travel Award
    2001AACR-AFLAC Scholar in Training Award,
    2006Donna and Jesse Garber Award

    Collapse Overview 
    Collapse Overview
    Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

    Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

    Collapse Research 
    Collapse Research Activities and Funding
    Selective Cancer Treatment Based on High Frequency Ultrasonic Beam
    NIH/NIBIB R21EB022932Sep 16, 2016 - Jul 31, 2018
    Role: Co-Principal Investigator
    Role of PIASy in Androgen Signaling and Prostate Cancer
    NIH/NIDDK K08DK064379Aug 21, 2002 - Jun 30, 2007
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Garri C, Howell S, Tiemann K, Tiffany A, Jalali-Yazdi F, Alba MM, Katz JE, Takahashi TT, Landgraf R, Gross M, Roberts RW, Kani K. Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2). Oncotarget. 2018 Jun 08; 9(44):27363-27379. PMID: 29937991.
      View in: PubMed
    2. Liao CP, Lin TP, Li PC, Geary LA, Chen K, Vaikari VP, Wu JB, Lin CH, Gross M, Shih JC. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene. 2018 May 29. PMID: 29844571.
      View in: PubMed
    3. Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross M, Dieli-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018 Apr 03; 18(1):368. PMID: 29614993.
      View in: PubMed
    4. Poon C, Chowdhuri S, Kuo CH, Fang Y, Alenghat FJ, Hyatt D, Kani K, Gross M, Chung EJ. Protein Mimetic and Anticancer Properties of Monocyte-Targeting Peptide Amphiphile Micelles. ACS Biomater Sci Eng. 2017 Dec 11; 3(12):3273-3282. PMID: 29302619.
      View in: PubMed
    5. Gross M, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. PMID: 28826933.
      View in: PubMed
    6. Kiwata JL, Dorff TB, Todd Schroeder E, Salem GJ, Lane CJ, Rice JC, Gross M, Dieli-Conwright CM. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. BMJ Open. 2017 Jul 10; 7(7):e016910. PMID: 28698349.
      View in: PubMed
    7. Tennill TA, Gross M, Frieboes HB. Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS One. 2017; 12(5):e0178362. PMID: 28552967.
      View in: PubMed
    8. Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross M. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr Relat Cancer. 2017 Apr; 24(4):157-170. PMID: 28264911.
      View in: PubMed
    9. Gross M. Blood-based gene expression profiling in castrate-resistant prostate cancer. BMC Med. 2015 Sep 14; 13:219. PMID: 26365516; PMCID: PMC4568585.
    10. van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross M, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ. Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. Urol Oncol. 2015 Nov; 33(11):495.e1-7. PMID: 26231310.
      View in: PubMed
    11. Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross M, Fini ME. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758. PMID: 25693195.
      View in: PubMed
    12. Ukimura O, Gross M, de Castro Abreu AL, Azhar RA, Matsugasumi T, Ushijima S, Kanazawa M, Aron M, Gill IS. A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel. Prostate. 2015 Jun; 75(8):863-71. PMID: 25663102.
      View in: PubMed
    13. Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S, Matsugasumi T, Gross M, Dasgupta P, Gill IS. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol. 2015 Nov; 33(11):1669-76. PMID: 25656687.
      View in: PubMed
    14. Dorff TB, Gross M. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; e270-3. PMID: 25993185.
      View in: PubMed
    15. Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross M, Hicks J, Kuhn P. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9(8):e101777. PMID: 25084170; PMCID: PMC4118839.
    16. Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross M, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. PMID: 24891013.
      View in: PubMed
    17. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross M, Shi Y, Webb IJ, Agus DB. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. PMID: 24418642.
      View in: PubMed
    18. Gross M. Prostate cancer: Age is nothing but a number. Nat Rev Urol. 2013 12; 10(12):683-4. PMID: 24217679.
      View in: PubMed
    19. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross M. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. PMID: 22911164.
      View in: PubMed
    20. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross M, Pinski JK, Quinn DI. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. PMID: 22691503; PMCID: PMC3375600.
    21. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross M. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):232-8. PMID: 22695254; PMCID: PMC3963491.
    22. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross M, Lieskovsky G, Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul; 62(1):55-63. PMID: 22445223.
      View in: PubMed
    23. Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross M, Agus DB. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. PMID: 22422671.
      View in: PubMed
    24. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross M, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. PMID: 22411897; PMCID: PMC3959865.
    25. Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, Gross M, Kuhn P. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol. 2012 Feb; 9(1):016002. PMID: 22306736; PMCID: PMC3387997.
    26. Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, Aron M, Gill IS. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012 Mar; 187(3):1080-6. PMID: 22266005.
      View in: PubMed
    27. Gross M, Leichman L, Lowe ES, Swaisland A, Agus DB. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. PMID: 22002543.
      View in: PubMed
    28. Dorff TB, Gross M. The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist. 2011; 16(10):1349-58. PMID: 21964003; PMCID: PMC3228074.
    29. Yu EY, Massard C, Gross M, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 May; 77(5):1166-71. PMID: 21539969; PMCID: PMC3394099.
    30. Quinn D, Gross M. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. PMID: 21310657.
      View in: PubMed
    31. Mink SR, Hodge A, Agus DB, Jain A, Gross M. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. PMID: 20564426.
      View in: PubMed
    32. Jiang Y, Palma JF, Agus DB, Wang Y, Gross M. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. PMID: 20581083.
      View in: PubMed
    33. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross M, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. PMID: 20336348; PMCID: PMC2917503.
    34. Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. PMID: 18756584.
      View in: PubMed
    35. Müller CI, Miller CW, Hofmann WK, Gross M, Walsh CS, Kawamata N, Luong QT, Koeffler HP. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res. 2007 Jan; 31(1):27-32. PMID: 16764926.
      View in: PubMed
    36. Shazer RL, Luthringer D, Agus DB, Gross M. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. PMID: 16163211.
      View in: PubMed
    37. Gross M, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. PMID: 15052539.
      View in: PubMed
    38. Gross M, Jo S, Agus DB. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. PMID: 16163160.
      View in: PubMed